Elena Garralda

Research interests

Publications

• Bispecific antibodies: advancing precision oncology

  Trends in cancer · 2024 · https://doi.org/10.1016/j.trecan.2024.07.002

• MYC targeting by OMO-103 in solid tumors: a phase 1 trial

  Nature Medicine · 2024 · https://doi.org/10.1038/s41591-024-02805-1

• Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

  Nature · 2024 · https://doi.org/10.1038/s41586-024-08305-z

• Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2303810

• Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

  Cancer Discovery · 2022 · https://doi.org/10.1158/2159-8290.cd-21-1345

• Delivering precision oncology to patients with cancer

  Nature Medicine · 2022 · https://doi.org/10.1038/s41591-022-01717-2

• Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.08.002

• Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity

  Cancer Discovery · 2022 · https://doi.org/10.1158/2159-8290.cd-22-0523

• Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

  Nature Medicine · 2022 · https://doi.org/10.1038/s41591-022-01931-y

• The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

  Nature Cancer · 2022 · https://doi.org/10.1038/s43018-022-00332-x

• Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

  The Lancet Diabetes & Endocrinology · 2021 · https://doi.org/10.1016/s2213-8587(21)00120-0

• Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00247-3

• Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours

  British Journal of Cancer · 2021 · https://doi.org/10.1038/s41416-021-01389-8

• Caring for patients with cancer in the COVID-19 era

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-0874-8

• Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2005653

• Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?

  Trends in cancer · 2020 · https://doi.org/10.1016/j.trecan.2020.01.005

• LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy

  Nature Communications · 2019 · https://doi.org/10.1038/s41467-019-10369-9

• Precision Targeted Therapy with BLU-667 for RET-Driven Cancers

  Cancer Discovery · 2018 · https://doi.org/10.1158/2159-8290.cd-18-0338

• Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment

  Clinical Cancer Research · 2014 · https://doi.org/10.1158/1078-0432.ccr-13-3047

• Level of HER2 Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2013.48.9070

• A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

  Journal of Hepatology · 2013 · https://doi.org/10.1016/j.jhep.2013.02.022

• Efficacy and Safety of Sorafenib in Combination With Mammalian Target of Rapamycin Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation

  Liver Transplantation · 2011 · https://doi.org/10.1002/lt.22434

Current projects

No projects listed.